NCT01448239 is a separate early-phase alirocumab study of single-dose safety, tolerability, pharmacokinetics and pharmacodynamics. The registration records 24 actual healthy adult participants and subcutaneous dosing. Regeneron's official trial page confirms the study's identity and these pharmacology objectives. 123

The relevant information is how exposure and biological measurements were characterized after a single dose, rather than a long-term comparison of cardiovascular events. It should not be merged with the 36-participant formulation study NCT01443650 merely because both concern alirocumab. 2

The inspected protocol provides the population and measurement framework but not a verified numerical exposure ratio, LDL reduction or adverse-event comparison. A later alirocumab outcomes trial would need its own citation and identifier; it cannot supply missing results for these 24 volunteers. 2